{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-004595","form_type":"8-K","ticker":"CATX","cik":"0000728387","company_name":"Perspective Therapeutics, Inc.","filed_at":"2025-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.211065+00:00","generated_at":"2026-05-28T04:08:34.598206+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Perspective Therapeutics reports $227.8M cash, updates on VMT-α-NET and VMT01 trials","bullets":["Preliminary unaudited cash, equivalents and ST investments: $227.8M as of Dec 31, 2024, funding operations into late 2026.","VMT-α-NET: 18 patients dosed in Cohort 2; data submitted to FDA; poster at ASCO-GI Jan 2025.","VMT01: SMC recommends 1.5 mCi dose as monotherapy and with nivolumab; both cohorts open for enrollment.","PSV359 IND filed late 2024; site activation underway, enrollment potentially mid-2025.","Four additional novel assets planned for first-in-human imaging in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-004595","json":"https://secwatch.observer/filing/0000950170-25-004595.json","markdown":"https://secwatch.observer/filing/0000950170-25-004595.md","text":"https://secwatch.observer/filing/0000950170-25-004595.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/728387/000095017025004595/0000950170-25-004595-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/728387/000095017025004595/catx-20250113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:08:34.598206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}